Hugel Aesthetics, the South Korean injectable manufacturer, is expanding its U.S. commercial footprint with a dedicated direct sales force for Letybo (its botulinum toxin) and a new K-TOX campaign. The move signals serious intent to compete head-to-head with AbbVie's Botox and Galderma's Dysport in the American market.
Business & M&A
Hugel Aesthetics Builds U.S. Direct Sales Force for Letybo and K-TOX Campaign
South Korean toxin maker invests in commercial infrastructure to challenge AbbVie and Galderma in the U.S. market.
1-YEAR MOVE
ABBV▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
Hugel is building direct U.S. sales infrastructure to challenge AbbVie and Galderma in the toxin market.
Letybo has gained traction in Asia and Europe on the strength of rapid onset (24–48 hours) and a favorable diffusion profile. A direct sales model in the U.S. is capital-intensive but allows Hugel to control messaging, pricing, and rebate strategy—critical levers in a market where Allergan and Galderma have long dominated through MSO partnerships and loyalty programs. For independent practices, this means a third credible toxin option with potential incentives to switch.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.